Trial Profile
An Evaluation of the Immune Response to Pentavalent Rotavirus Vaccine After a Supplemental Dose Given at 9 Months of Age With Local EPI Vaccines in Mali
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Dec 2021
Price :
$35
*
At a glance
- Drugs Rotavirus W179-9 vaccine (Primary) ; Measles vaccines; Meningococcal vaccine conjugate; Yellow fever vaccine
- Indications Rotavirus infections
- Focus Pharmacodynamics
- 12 Apr 2018 Primary endpoint (The immune response will be parameterized as the yellow fever virus neutralizing antibody seroconversion rate) has not been met as per the results published in the Journal of Infectious Diseases.
- 12 Apr 2018 Primary endpoint (The immune response will be parameterized as the measles virus neutralizing antibody seroconversion rate) has been met as per the results published in the Journal of Infectious Diseases.
- 12 Apr 2018 Results published in the Journal of Infectious Diseases